Navigation Links
The PROOF Centre of Excellence Partners with OriGene Technologies on Heart & Kidney Transplant Biomarker Program

ROCKVILLE, Md., July 19, 2012 /PRNewswire/ -- OriGene Technologies, Inc. and Canada's Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) today announced the selection of OriGene Technologies as a major collaboration and development partner to implement blood-based protein assays in heart and kidney transplantation. This multi-year, collaborative project funded by multiple partners will provide monitoring and predictive blood tests, based upon OriGene's extensive expertise in immunoassay and antibody development, to improve the care of heart and kidney transplant patients worldwide.

OriGene Technologies, as a leading assay development partner for the project, will leverage its industry leading collection of gene-centric tools, high quality monoclonal antibody validation technologies, and expertise in Luminex® multiplex assay development to create diagnostic assays for the clinical transplantation environment and integrate these novel tools to improve patient care. This is the first announced clinical development project that will utilize OriGene's highly validated and "mono-specific" antibodies known as UltraMAB™ Antibodies. UltraMAb antibodies are a newly released class of antibody products validated for specificity and low cross-reactivity, thus reducing potential side effects or false diagnostic reports in clinical studies.

According to a recently completed economic evaluation prepared by the PROOF Centre, the reduction in the costs from implementing blood based tests in organ rejection could result in savings of $700,000 over 5 years for the heart and kidney transplant programs in British Columbia. Furthermore, implementation of such tests would dramatically improve the quality of life for heart and kidney transplant patients and reduce the need for costly biopsies, which have no predictive value in measuring acute graft rejection, one of the most important causes of early morbidity and graft injury in organ transplantation patients.

"We are excited to be working with OriGene to utilize its collection of gene-centric tools and assay development expertise to positively impact the lives of patients experiencing heart and kidney transplantation. Through the success of our close collaboration, our ultimate goal is to meet an unmet clinical need in these patients through the development of accurate, high quality blood tests to reduce the risks, pain, and fear associated with current practices for detecting organ rejection," commented Dr. Bruce McManus, Director of the PROOF Centre.

Through the combined efforts of leading research institutes and commercial organizations, such as the PROOF Centre and OriGene, biomarker discovery and development are being effectively applied and moved to the clinical environment to address real world challenges faced by the global healthcare market. By creating novel classes of blood tests to monitor transplant patients, The PROOF Centre and OriGene are collaborating to usher in a new era of personalized medicine and integrating "omics" technologies to deliver a significant impact upon patient care.

"By applying our novel technologies and unique expertise in assay development to the challenges in the transplantation market, OriGene is has truly embarked on its mission to provide comprehensive technology solutions for biomarker development. We are pleased to have been selected as the premiere development partner for this critical project and playing a significant role in improving the quality of life for all patients in the global transplantation market" commented Dr. Wei-Wu He, Ph.D. CEO & Chairman, OriGene Technologies.

OriGene Technologies uses a high-throughput, genome wide approach to develop products for pharmaceutical, biotechnology, and academic research. The Company's flagship product is its cDNA clone collection, a searchable gene bank of over 30,000 human full-length TrueClone cDNA clones and over 25,000 TrueORF cDNA clones. From the TrueORF cDNA clones, OriGene has developed the largest offering of full length human proteins expressed in mammalian cells available. Recently, OriGene has embarked upon the development of the UltraMAB Antibodies, the industry's only "specificity-verified" and "mono-specific" monoclonal antibodies available and designed for diagnostic, as well as therapeutic applications.  Created through proprietary antibody validation technology, UltraMAB antibodies are a new paradigm in antibody accuracy and superior performance in antibody based applications.

About OriGene Technologies

OriGene Technologies, Inc. is a biosciences company dedicated to develop gene centric innovative products and services to improve the quality of healthcare diagnostics and treatments.   The Company's broadest collection of gene based products and services are important tools to accelerate the discovery of new diagnostics and drug treatments for better patient care.  OriGene has one of the largest scale antibody production and highest quality process facilities in the world.  For more information, visit

About the PROOF Centre of Excellence

The Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) discovers, develops, commercializes and implements biomarkers to prevent, predict, diagnose and better treat and manage heart, lung and kidney disease. The PROOF Centre is a cross-disciplinary engine of partners representing academia, health care, government, industry, patients and the public, focused on improving health and reducing the enormous socioeconomic burden of heart, lung and kidney disease.

The PROOF Centre is a not-for-profit society established in March 2008 by competitive funding from the Networks of Centres of Excellence Secretariat under the Centre of Excellence for Commercialization and Research (NCE CECR) Program. The PROOF Centre is co-hosted by the University of British Columbia and Providence Health Care in Vancouver, British Columbia. For more information visit

SOURCE OriGene Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Quality Salivary Research with the Salimetrics Center of Excellence Program
2. Exotic Automation & Supply Receives Ford’s 2011 World Excellence Award
3. Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy
4. UBM Canon, the Global MedTech Authority, and the Medical Design Excellence Awards Announce Dean Kamen as the Presenter of the 2012 Lifetime Achievement Award
5. AlphaVax Announces Nomination for 2012 Vaccine Industry Excellence Award
6. Professor Doel Soejarto to Receive ABCs Farnsworth Excellence in Botanical Research Award
7. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
8. NineSigma Partners with Scientists Without Borders to Find New Sustainable Packaging for Micronutrient Powders that Combat Malnutrition
9. HemoShear Partners with Expression Analysis (EA) to Develop a Human Drug-Induced Vascular Response Database
10. Elsevier and The Geological Society of London Take Home the 2012 Getenergy Award for Education / Industry Partnership
11. Clean Energy Alliance and the Manufacturing Extension Partnership Announce New Collaboration
Post Your Comments:
(Date:11/24/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. ... will provide a corporate overview. th Annual Oppenheimer ... p.m. ET/10:00 a.m. PT . Jim Mazzola , vice ... overview. --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - Aeterna ... request of IIROC on behalf of the Toronto Stock ... news release there are no corporate developments that would ... --> --> About ... . --> Aeterna Zentaris is ...
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model ... Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the First–Person View ... years. Many AMA members have embraced this type of racing and several new model ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... the remaining 11,000 post-share consolidation (or 1,100,000 pre-share ... "Series B Warrants") subject to the previously disclosed ... 23, 2015, which will result in the issuance ... to the issuance of such shares, there will ...
Breaking Biology Technology:
(Date:10/26/2015)... ALTO, Calif. and LAS VEGAS ... Nok Nok Labs , an innovator in modern ... Alliance , today announced the launch of its latest ... first unified platform enabling organizations to use standards-based authentication ... The Nok Nok S3 Authentication Suite is ideal for ...
(Date:10/23/2015)... 23, 2015 Research and Markets ( ... Voice Recognition Biometrics Market 2015-2019" report to their ... The global voice recognition biometrics market to grow ... --> --> The report, ... based on an in-depth market analysis with inputs from ...
(Date:10/22/2015)... AWRE ), a leading supplier of biometrics software and services, ... 2015.  --> --> Revenue ... of 33% compared to $6.0 million in the same quarter last ... million, or $0.10 per diluted share, which compared to $2.6 million, ... ago.  --> --> Lower ...
Breaking Biology News(10 mins):